open access

Vol 69, No 9 (2011)
Original articles
Published online: 2011-09-19
Submitted: 2012-12-28
Get Citation

Increased prevalence of cardiovascular risk factors in patients with acute coronary syndrome and indications for treatment with oral anticoagulation

Michał Owsiak, Agnieszka Pelc-Nowicka, Leszek Badacz, Jacek Dubiel, Dariusz Dudek, Grzegorz Gajos, Janusz Grodecki, Piotr Jankowski, Kalina Kawecka-Jaszcz, Ewa Mirek-Bryniarska, Jadwiga Nessler, Piotr Podolec, Jerzy Sadowski, Wiesława Tracz, Michał Zabojszcz, Krzysztof Żmudka, Leszek Bryniarski
Kardiol Pol 2011;69(9):907-912.

open access

Vol 69, No 9 (2011)
Original articles
Published online: 2011-09-19
Submitted: 2012-12-28

Abstract

Background: Antiplatelet drugs currently constitute the basic treatment of coronary artery disease (acute coronary syndrome [ACS], stable angina and patients treated with percutaneous coronary interventions [PCI]). The number of patients with indication for dual antiplatelet therapy with comorbidities with high thrombo-embolic risk (such as atrial fibrillation [AF], venous thrombotic disease, valvular diseases) is increasing. That is why the need for simultaneous administration of dual antiplatelet and oral anticoagulant therapy (triple therapy) has become more common recently. The AF is the most common indication for chronic anticoagulation. Because of the lack of large randomised trials regarding triple therapy, characteristics of this group has not been well established.
Aim: To assess the presence of cardiovascular (CV) risk factors and concomitant diseases in patients with ACS requiring triple therapy.
Methods: Retrospective analysis included 2279 patients diagnosed with ACS who were admitted to the Departments of Cardiology in Cracow in 2008. In this group, 365 (16%) patients had indications for chronic anticoagulation. Demographic and clinical characteristics of these patients were compared with those of patients included in other published registries.
Results: Patients requiring triple therapy were aged 73.2 ± 9.5 years. Hypertension was diagnosed in 80%, hyperlipidaemia in 63%, smoking in 36%, prior myocardial infarction in 33%, prior stroke in 15%, previous treatment with PCI in 13%, coronary artery bypass grafting in 7%, diabetes in 36%, heart failure in 46%, anaemia in 33% and chronic ulcer disease or gastroesophageal reflux disease in 9%. The mean left ventricular ejection fraction was 46 ± 15%. Compared with other registries of patients without indications for triple therapy, our patients had significantly more frequently hypertension, diabetes and were older.
Conclusions: Patients after an ACS requiring triple therapy have more often a history of comorbidities and CV risk factors when compared with the group of patients with ACS without indication for triple therapy.
Kardiol Pol 2011; 69, 9: 907–912

Abstract

Background: Antiplatelet drugs currently constitute the basic treatment of coronary artery disease (acute coronary syndrome [ACS], stable angina and patients treated with percutaneous coronary interventions [PCI]). The number of patients with indication for dual antiplatelet therapy with comorbidities with high thrombo-embolic risk (such as atrial fibrillation [AF], venous thrombotic disease, valvular diseases) is increasing. That is why the need for simultaneous administration of dual antiplatelet and oral anticoagulant therapy (triple therapy) has become more common recently. The AF is the most common indication for chronic anticoagulation. Because of the lack of large randomised trials regarding triple therapy, characteristics of this group has not been well established.
Aim: To assess the presence of cardiovascular (CV) risk factors and concomitant diseases in patients with ACS requiring triple therapy.
Methods: Retrospective analysis included 2279 patients diagnosed with ACS who were admitted to the Departments of Cardiology in Cracow in 2008. In this group, 365 (16%) patients had indications for chronic anticoagulation. Demographic and clinical characteristics of these patients were compared with those of patients included in other published registries.
Results: Patients requiring triple therapy were aged 73.2 ± 9.5 years. Hypertension was diagnosed in 80%, hyperlipidaemia in 63%, smoking in 36%, prior myocardial infarction in 33%, prior stroke in 15%, previous treatment with PCI in 13%, coronary artery bypass grafting in 7%, diabetes in 36%, heart failure in 46%, anaemia in 33% and chronic ulcer disease or gastroesophageal reflux disease in 9%. The mean left ventricular ejection fraction was 46 ± 15%. Compared with other registries of patients without indications for triple therapy, our patients had significantly more frequently hypertension, diabetes and were older.
Conclusions: Patients after an ACS requiring triple therapy have more often a history of comorbidities and CV risk factors when compared with the group of patients with ACS without indication for triple therapy.
Kardiol Pol 2011; 69, 9: 907–912
Get Citation

Keywords

acute coronary syndrome; oral anticoagulant therapy; triple therapy; cardiovascular risk factors

About this article
Title

Increased prevalence of cardiovascular risk factors in patients with acute coronary syndrome and indications for treatment with oral anticoagulation

Journal

Kardiologia Polska (Polish Heart Journal)

Issue

Vol 69, No 9 (2011)

Pages

907-912

Published online

2011-09-19

Bibliographic record

Kardiol Pol 2011;69(9):907-912.

Keywords

acute coronary syndrome
oral anticoagulant therapy
triple therapy
cardiovascular risk factors

Authors

Michał Owsiak
Agnieszka Pelc-Nowicka
Leszek Badacz
Jacek Dubiel
Dariusz Dudek
Grzegorz Gajos
Janusz Grodecki
Piotr Jankowski
Kalina Kawecka-Jaszcz
Ewa Mirek-Bryniarska
Jadwiga Nessler
Piotr Podolec
Jerzy Sadowski
Wiesława Tracz
Michał Zabojszcz
Krzysztof Żmudka
Leszek Bryniarski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl